EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Open Access · CC BY-NC-ND 4.0

Effect of carbamazepine on the pharmacokinetics of vepdegestrant, a PROteolysis TArgeting Chimera estrogen receptor degrader, in healthy adults

Hechuan Wang iD, Jennifer A Winton, Kyle T Matschke, Alexandre Stouffs iD, Kimberly C Lee, Yuanyuan Zhang, Wenlian Qiao, Weiwei Tan iD

British Journal of Clinical Pharmacology · 2026

DOI: 10.1002/bcp.70482 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift British Journal of Clinical Pharmacology, 2026. Verfasst von Hechuan Wang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Pfizer, Inc., La Jolla, California, USA. Hauptthemen laut MEDLINE: Carbamazepine, Cytochrome P-450 CYP3A Inducers. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Pfizer, Inc., Arvinas Estrogen Receptor, Inc..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

To evaluate the effects of carbamazepine, a strong cytochrome P450 (CYP)3A4 inducer, on the pharmacokinetics and safety of vepdegestrant, a PROteolysis TArgeting Chimera estrogen receptor degrader.

Methods

This was a phase 1, open‐label, fixed‐sequence, two‐period study in healthy adult participants. During Period 1, a single oral dose of vepdegestrant 200 mg was administered (Day 1). During Period 2, carbamazepine dosing was titrated from 200 mg orally once daily (Days 1–3) to twice (Days 4–7) and three times daily (Days 8–19); a single oral dose of vepdegestrant 200 mg was administered (Day 14). Blood samples for pharmacokinetics analysis were collected up to 144 h after dosing in both periods. Safety was monitored throughout the study.

Results

Twelve healthy male participants were enrolled and treated. Following administration of vepdegestrant with (test) and without (reference) carbamazepine, test/reference ratios (90% confidence intervals) of the adjusted geometric means for vepdegestrant area under the plasma concentration–time curve from time 0 to infinity and maximum plasma concentration were 64.1% (60.0% to 68.4%) and 80.2% (74.0% to 86.8%), respectively. Similar decreases in ARV‐473 (vepdegestrant epimer) exposure were observed. Two participants discontinued during Period 2 due to elevated liver enzymes and maculopapular rash (both unrelated to vepdegestrant; one participant each).

Conclusion

Coadministration of multiple doses of carbamazepine 200 mg, a strong CYP3A4 inducer, with a single dose of vepdegestrant 200 mg resulted in a modest (36%) decrease in plasma vepdegestrant exposure. A single dose of vepdegestrant 200 mg was well tolerated in healthy adult participants. Clinical trial registration : NCT06005688.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CarbamazepineCytochrome P-450 CYP3A InducersHumansMaleAdultDrug InteractionsYoung AdultCytochrome P-450 CYP3AMiddle AgedProteolysis Targeting ChimeraHealthy VolunteersArea Under CurveAdministration, Oral

Stichwörter der Autor:innen

cytochrome P450 (pharmacokinetics)drug interactions (pharmacokinetics)oncology (breast cancer)phase I (drug development)

Substanzen

CarbamazepineCytochrome P-450 CYP3ACytochrome P-450 CYP3A InducersCYP3A4 protein, humanProteolysis Targeting Chimera

Autor:innen und Institutionen

  • Pfizer, Inc., La Jolla, California, USA.
  • Pfizer, Inc., Groton, Connecticut, USA.
  • Pfizer, Inc., Collegeville, Pennsylvania, USA.
  • Pfizer Clinical Research Unit, Brussels, Belgium.
  • Arvinas Operations, Inc., New Haven, Connecticut, USA.

ORCID-Profile: Hechuan Wang, Alexandre Stouffs, Weiwei Tan

Förderung

  • Pfizer, Inc.
  • Arvinas Estrogen Receptor, Inc.

Zitieren

APA

Wang, H., Winton, J. A., Matschke, K. T., Stouffs, A., Lee, K. C., Zhang, Y., Qiao, W., & Tan, W. (2026). Effect of carbamazepine on the pharmacokinetics of vepdegestrant, a PROteolysis TArgeting Chimera estrogen receptor degrader, in healthy adults. British Journal of Clinical Pharmacology. https://doi.org/10.1002/bcp.70482

Vancouver

Wang H, Winton JA, Matschke KT, Stouffs A, Lee KC, Zhang Y, et al. Effect of carbamazepine on the pharmacokinetics of vepdegestrant, a PROteolysis TArgeting Chimera estrogen receptor degrader, in healthy adults. British Journal of Clinical Pharmacology. 2026. doi:10.1002/bcp.70482

BibTeX
@article{Wang2026,
  author = {Wang, Hechuan and Winton, Jennifer A and Matschke, Kyle T and Stouffs, Alexandre and Lee, Kimberly C and Zhang, Yuanyuan and Qiao, Wenlian and Tan, Weiwei},
  title = {Effect of carbamazepine on the pharmacokinetics of vepdegestrant, a PROteolysis TArgeting Chimera estrogen receptor degrader, in healthy adults},
  journal = {British Journal of Clinical Pharmacology},
  year = {2026},
  doi = {10.1002/bcp.70482}
}
Kostenlos starten →